亚太膀胱癌治疗和诊断市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

亚太膀胱癌治疗和诊断市场按产品(治疗、诊断)、癌症类型和地理划分。

市场快照

Market Snapshot
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

由于膀胱癌负担增加以及市场上出现新的诊断和治疗方法,亚太膀胱癌治疗和诊断市场预计在预测期内的复合年增长率为 5%。根据 Globocan 的数据,2018 年,日本新登记了约 37,293 例膀胱癌病例,约 9,943 人因此死亡。这就需要早期治疗和诊断。此外,正在开发治疗膀胱癌的新药。2020年,百济神州抗PD-1抗体替雷利珠单抗治疗局部晚期或转移性尿路上皮癌(UC)获得国家药品监督管理局(NMPA)批准。因此,预计这些因素将推动市场的增长。

Scope of the report

Bladder cancer is a type of tumor that occurs in the cells of the bladder. It grows rapidly and shows uncontrolled growth in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market is segmented by Product, by Cancer Type, and Geography.

By Product
By Therapeutics
Chemotherapy
Immunotherapy
Others
By Diagnostics
Cystoscopy
Bladder Ultrasound
Urinalysis
Others
By Cancer Type
Transitional Cell Bladder Cancer
Squamous Cell Bladder Cancer
Others
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

主要市场趋势

膀胱超声有望在预测期内呈现稳定增长

膀胱超声是一种使用声波来检测和分析膀胱中存在的癌症的诊断设备。膀胱癌的发病率不断上升,并且正在开发用于诊断癌症的新设备,预计将刺激这一领域的增长。根据 Globocan 的数据,2018 年,大韩民国观察到近 4,249 例膀胱癌发病率,约 1,712 人死亡。由于其特异性,超声是诊断癌症早期阶段最常用的方法。因此,预计在预测期内将增加市场对超声设备的需求。

APAC BC D&T Market Trends Image.png

竞争格局

市场上的一些主要参与者包括阿斯利康、百时美施贵宝公司、礼来公司、F. Hoffmann-La Roche Ltd、葛兰素史克、诺华、辉瑞、赛诺菲、远藤制药和强生。公司不断沉迷于开发与膀胱癌诊断和治疗相关的产品,以扩大其在市场上的占有率。2018年,默克公司的产品Keytruda(MSD)获得日本厚生劳动省(MHLW)的批准,用于治疗尿路上皮癌患者。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Bladder Cancer

      2. 4.2.2 Innovation in Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Increased Used of Generic Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 By Therapeutics

        1. 5.1.1.1 Chemotherapy

        2. 5.1.1.2 Immunotherapy

        3. 5.1.1.3 Others

      2. 5.1.2 By Diagnostics

        1. 5.1.2.1 Cystoscopy

        2. 5.1.2.2 Bladder Ultrasound

        3. 5.1.2.3 Urinalysis

        4. 5.1.2.4 Others

    2. 5.2 By Cancer Type

      1. 5.2.1 Transitional Cell Bladder Cancer

      2. 5.2.2 Squamous Cell Bladder Cancer

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 Asia-Pacific

        1. 5.3.1.1 China

        2. 5.3.1.2 Japan

        3. 5.3.1.3 India

        4. 5.3.1.4 Australia

        5. 5.3.1.5 South Korea

        6. 5.3.1.6 Rest of Asia-Pacific

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca Plc

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 Eli Lilly & Company

      4. 6.1.4 Endo Pharmaceuticals Inc.

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 GlaxoSmithKline

      7. 6.1.7 Novartis

      8. 6.1.8 Pfizer

      9. 6.1.9 Sanofi

      10. 6.1.10 Johnson & Johnson

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market market is studied from 2018 - 2026.

The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market is growing at a CAGR of 5% over the next 5 years.

F. Hoffmann-La Roche Ltd, Johnson & Johnson, Endo Pharmaceutical Inc., AstraZeneca Plc, Bristol-Myers Squibb Company are the major companies operating in Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!